GlassScriptPhysician profile
Sabre Thomas Watkins
NPI 1508372392
$4,531.14
in general payments reported to CMS, 2019-2025
20 companies · $914 in 2025
The $914 reported for 2025 was more than what 79% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $635 · 2022: $518 · 2023: $1,397 · 2024: $1,067 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,378.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $809.59 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $599.01 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $444.32 | 2021-2023 | Uzedy, Austedo Xr |
| Alnylam Pharmaceuticals INC. | $440.83 | 2021-2025 | Amvuttra, Givlaari |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $306.18 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $291.01 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $253.44 | 2023-2025 | |
| Alkermes, INC. | $247.26 | 2021-2025 | Lybalvi |
| Vanda Pharmaceuticals INC. | $225.84 | 2024-2025 | Fanapt |
| Astrazeneca Pharmaceuticals LP | $134.70 | 2023 | Farxiga |
| Argenx US, INC. | $133.73 | 2023 | Vyvgart |
| Axsome Therapeutics, INC. | $124.36 | 2024 | Auvelity |
| Ironshore Pharmaceuticals INC. | $109.73 | 2023 | Jornay Pm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.16 | 2021 | |
| Amgen INC. | $98.92 | 2025 | Krystexxa |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioxcel Therapeutics, INC. | $90.32 | 2023 | Igalmi |
| Gilead Sciences, INC. | $43.95 | 2021 | |
| Viiv Healthcare Company | $34.00 | 2021 | |
| Novo Nordisk INC | $21.99 | 2023 | |
| Supernus Pharmaceuticals, INC. | $12.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabre Watkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.